Patents by Inventor Connie Sanchez
Connie Sanchez has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 6960613Abstract: Use of escitalopram (the S-(+)-enantiomer of citalopram) or a pharmaceutically acceptable salt thereof for the preparation of a medicament useful in the treatment of neurotic disorders is provided, including anxiety states, in particular generalised anxiety disorder and social anxiety disorder, post traumatic stress disorder, obsessive compulsive disorder and panic attacks.Type: GrantFiled: August 20, 2003Date of Patent: November 1, 2005Assignee: H. Lundbeck A/SInventors: Connie Sanchez, Sandra Hogg
-
Publication number: 20050234093Abstract: The present invention relates to use of gaboxadol for preparing a pharmaceutical composition for treating depression. Moreover, it relates to the use of gaboxadol for the preparation of a pharmaceutical composition to be used in combination with a serotonin reuptake inhibitor, or any other compound which causes an elevation in the level of extracellular serotonin.Type: ApplicationFiled: December 22, 2004Publication date: October 20, 2005Applicant: H. Lundbeck A/SInventors: Connie Sanchez, Bjarke Ebert
-
Publication number: 20050101665Abstract: Use of escitalopram (the S-(+)-enantiomer of citalopram) or a pharmaceutically acceptable salt thereof for the preparation of a medicament useful in the treatment of neurotic disorders is provided, including anxiety states, in particular generalised anxiety disorder and social anxiety disorder, post traumatic stress disorder, obsessive compulsive disorder and panic attacks.Type: ApplicationFiled: August 20, 2003Publication date: May 12, 2005Applicant: H. Lundbeck A/SInventors: Connie Sanchez, Sandra Hogg
-
Publication number: 20050101666Abstract: The present invention relates to a method of treating the symptoms of premenstrual dysphoric disorder (PMDD) in a patient in need thereof by administering an effective amount of escitalopram or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: November 8, 2004Publication date: May 12, 2005Applicant: H. Lundbeck A/SInventor: Connie Sanchez
-
Publication number: 20040198811Abstract: The present invention relates to the use of anantiomeric pure escitalopram and/or of low dose medicaments thereof for the improved treatment of depression, in particular major depression disorder, neurotic disorders, acute stress disorder, eating disorders such as bulimia, anorexia and obesity, phobias, dysthymia, pre-mentrual syndrome, cognitive disorders, impulse control disorders, attention deficit hyperactivity disorder or drug abuse. The medicaments may also be used in the treatment of major depression disorder in “treatment resistant” patients.Type: ApplicationFiled: August 20, 2003Publication date: October 7, 2004Applicant: H. Lundbeck A/SInventors: Connie Sanchez, Jesper Lyng Jensen, Arne Mork
-
Publication number: 20040198809Abstract: The present invention relates to the use of enantiomeric pure escitalopram and/or of low dose medicaments thereof for the improved treatment of depression, in particular major depression disorder, neurotic disorders, acute stress disorder, eating disorders such as bulimia, anorexia and obesity, phobias, dysthymia, pre-menstrual syndrome, cognitive disorders, impulse control disorders, attention deficit hyperactivity disorder or drug abuse. The medicaments may also be used in the treatment of major depression disorder in “treatment resitant” patients.Type: ApplicationFiled: June 8, 2004Publication date: October 7, 2004Inventors: Connie Sanchez, Arne Mork
-
Publication number: 20040198810Abstract: The present invention relates to the use of anantiomeric pure escitalopram and/or of low dose medicaments thereof for the improved treatment of depression, in particular major depression disorder, neurotic disorders, acute stress disorder, eating disorders such as bulimia, anorexia and obesity, phobias, dysthymia, pre-mentrual syndrome, cognitive disorders, impulse control disorders, attention deficit hyperactivity disorder or drug abuse. The medicaments may also be used in the treatment of major depression disorder in “treatment resistant” patients.Type: ApplicationFiled: August 20, 2003Publication date: October 7, 2004Applicant: H. Lundbeck A/SInventors: Connie Sanchez, Jesper Lyng Jensen, Arne Mork
-
Publication number: 20040192764Abstract: The present invention relates to the use of an antiomeric pure escitalopram and/or of low dose medicaments thereof for the improved treatment of depression, in particular major depression disorder, neurotic disorders, acute stress disorder, eating disorders such as bulimia, anorexia and obesity, phobias, dysthymia, pre-mentrual syndrome, cognitive disorders, impulse control disorders, attention deficit hyperactivity disorder or drug abuse. The medicaments may also be used in the treatment of major depression disorder in “treatment resistant” patients.Type: ApplicationFiled: August 20, 2003Publication date: September 30, 2004Applicant: H. Lundbeck A/SInventors: Connie Sanchez, Jesper Lyng Jensen, Arne Mork
-
Publication number: 20040192766Abstract: The present invention relates to the use of anantiomeric pure escitalopram and/or of low dose medicaments thereof for the improved treatment of depression, in particular major depression disorder, neurotic disorders, acute stress disorder, eating disorders such as bulimia, anorexia and obesity, phobias, dysthymia, pre-mentrual syndrome, cognitive disorders, impulse control disorders, attention deficit hyperactivity disorder or drug abuse. The medicaments may also be used in the treatment of major depression disorder in “treatment resistant” patients.Type: ApplicationFiled: August 20, 2003Publication date: September 30, 2004Applicant: H. Lundbeck A/SInventors: Connie Sanchez, Jesper Lyng Jensen, Arne Mork
-
Publication number: 20040192765Abstract: The present invention relates to the use of anatiomeric pure escitalopram and/or of low dose medicaments thereof for the improved treatment of depression, in particular major depression disorder, neurotic disorders, acute stress disorder, eating disorders such as bulimia, anorexia and obesity, phobias, dysthymia, pre-mentrual syndrome, cognitive disorders, impulse control disorders, attention deficit hyperactivity disorder or drug abuse. The medicaments may also be used in the treatment of major depression disorder in “treatment resistant” patients.Type: ApplicationFiled: August 20, 2003Publication date: September 30, 2004Applicant: H. Lundbeck A/SInventors: Connie Sanchez, Jesper Lyng Jensen, Arne Mork
-
Publication number: 20040029957Abstract: Use of escitalopram (the S-(+)-enantiomer of citalopram) or a pharmaceutically acceptable salt thereof for the preparation of a medicament useful in the treatment of neurotic disorders is provided, including anxiety states, in particular generalised anxiety disorder and social anxiety disorder, post traumatic stress disorder, obsessive compulsive disorder and panic attacks.Type: ApplicationFiled: August 7, 2003Publication date: February 12, 2004Applicant: H. Lundbeck A/SInventors: Connie Sanchez, Sandra Hogg
-
Publication number: 20040029956Abstract: Use of escitalopram (the S-(+)-enantiomer of citalopram) or a pharmaceutically acceptable salt thereof for the preparation of a medicament useful in the treatment of neurotic disorders is provided, including anxiety states, in particular generalised anxiety disorder and social anxiety disorder, post traumatic stress disorder, obsessive compulsive disorder and panic attacks.Type: ApplicationFiled: August 7, 2003Publication date: February 12, 2004Applicant: H. Lundbeck A/SInventors: Connie Sanchez, Sandra Hogg
-
Publication number: 20040029958Abstract: Use of escitalopram (the S-(+)-enantiomer of citalopram) or a pharmaceutically acceptable salt thereof for the preparation of a medicament useful in the treatment of neurotic disorders is provided, including anxiety states, in particular generalised anxiety disorder and social anxiety disorder, post traumatic stress disorder, obsessive compulsive disorder and panic attacks.Type: ApplicationFiled: August 7, 2003Publication date: February 12, 2004Applicant: H. Lundbeck A/SInventors: Connie Sanchez, Sandra Hogg
-
Publication number: 20020086899Abstract: Use of escitalopram (the S-(+)-enantiomer of citalopram) or a pharmaceutically acceptable salt thereof for the preparation of a medicament useful in the treatment of neurotic disorders is provided, including anxiety states, in particular generalised anxiety disorder and social anxiety disorder, post traumatic stress disorder, obsessive compulsive disorder and panic attacks.Type: ApplicationFiled: December 12, 2001Publication date: July 4, 2002Applicant: H. Lundbeck A/SInventors: Connie Sanchez, Sandra Hogg
-
Patent number: 6358966Abstract: The compound 1′-[4-[1-(4-fluorophenyl)-1H-indole-3-yl]-1-butyl-spiro[isobenzo-furan-1(3H,4′-piperidine] is active in models predictive of antidepressant effects and is useful for the preparation of a medicament for the treatment of depression or diseases associated with depressive symptoms.Type: GrantFiled: March 15, 2001Date of Patent: March 19, 2002Assignee: H. Lundbeck A/SInventor: Connie Sanchez
-
Publication number: 20010020027Abstract: The compound 1′-[4-[1-(4-fluorophenyl)-1H-indole-3-yl]-1-butyl-spiro[isobenzofuran-1(3H,4′-piperidine] is active in models predictive of antidepressant effects and is useful for the preparation of a medicament for the treatment of depression or diseases associated with depressive symptoms.Type: ApplicationFiled: March 15, 2001Publication date: September 6, 2001Applicant: H. Lundbeck A/SInventor: Connie Sanchez
-
Patent number: 6262061Abstract: The compound 1′-[4-[1-(4-fluorophenyl)-1H-indole-3-yl]-1-butyl]-spiro[isobenzo-furan-1(3H),4′-piperidine] is active in models predictive of effect on panic attacks and is useful for the preparation of a medicament for the treatment of diseases associated with panic attacks.Type: GrantFiled: October 6, 2000Date of Patent: July 17, 2001Assignee: H. Lundbeck A/SInventors: Connie Sanchez, Sandra Hogg, Maria Jessa